Hayashida, DK

Kellum, JA

Khangulov, V

Lobo, DN

Munson, SH

Schermer, CR

Shaw, AD

D-Scholarship@Pitt

Shaw et al. Critical Care  (2016) 20:17 DOI 10.1186/s13054-016-1187-7ERRATUM Open AccessErratum to: Impact of intravenous fluidcomposition on outcomes in patients withsystemic inflammatory response syndromeAndrew D. Shaw1*, Carol R. Schermer2, Dileep N. Lobo3, Sibyl H. Munson4, Victor Khangulov4,David K Hayashida4 and John A. Kellum5After the publication of this article it has been broughtto our attention that the data in Table 3 (Table 1 in thisErratum) and in the Additional file 3: Table S3(Additional File 1 in this Erratum) contained mistakes asdetailed below. These mistakes have been corrected inthis Erratum.The following values have been corrected in Table 3(Table 1 in this Erratum): the entire column (far right) "Adjusted Odds Ratio(95 % CI)" under Electrolyte Abnormalities, the value for "HighMg" within the column "Saline n (%)" and the valuesfor "Unadjusted Odds Raio (95 % CI)" and "AdjustedOdds Ratio (95 % CI)" under Electrolyte Abnormalities, ALL values for therow labelled "Low Ca with replacement"The single value for SOFA CV Level 2 "Saline cohortn (%)" in Table S3 (Additional File 1 in this Erratum) hasbeen corrected.In addition, we noticed that the legend for Fig. 2 (Fig. 1in this Erratum) was incorrectly given as “Administrativeand clinical outcomes unadjusted and adjusted for AcutePhysiology Score”. The correct legend for Fig. 2 is“Administrative and clinical outcomes unadjusted andadjusted for APS, Elixhauser comorbidities of congestiveheart failure, hypertension and lymphoma, admissionsource, census region, and payer.” The labels above theright-hand side plots within the figure also needed correc-tions and have been updated in this erratum.* Correspondence: andrew.shaw@vanderbilt.edu1Department of Anesthesiology, Vanderbilt University Medical Center, 121521st Avenue S., Suite 5160 MCE NT, Office 5163, Campus Box 8274, Nashville37232-8274 TN, USAFull list of author information is available at the end of the article© 2016 Shaw et al. Open Access This article iInternational License (http://creativecommonsreproduction in any medium, provided you gthe Creative Commons license, and indicate if(http://creativecommons.org/publicdomain/zeAdditional fileAdditional file 3: Table S3. SOFA Outcomes by Treatment Group.(DOCX 12 kb)Author details1Department of Anesthesiology, Vanderbilt University Medical Center, 121521st Avenue S., Suite 5160 MCE NT, Office 5163, Campus Box 8274, Nashville37232-8274 TN, USA. 2Former Employee Baxter Healthcare Corporation, 1Baxter Parkway, Deerfield 60015 IL, USA. 3Gastrointestinal Surgery, NationalInstitute for Health Research Nottingham Digestive Diseases BiomedicalResearch Unit, Nottingham University Hospitals and University ofNottingham, Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH,UK. 4Boston Strategic Partners, Inc., 4 Wellington Street, Boston 02118MA,USA. 5Center for Critical Care Nephrology, Department of Critical CareMedicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh 15261 PA,USA.Received: 27 October 2015 Accepted: 6 November 2015Reference1. Shaw AD, Schermer CR, Lobo DN, Munson SH, Khangulov V, Hayashida DK,et al. Impact of intravenous fluid composition on outcomes in patients withsystemic inflammatory response syndrome. Critical Care. 2015;19:334.Submit your next manuscript to BioMed Centraland take full advantage of: • Convenient online submission• Thorough peer review• No space constraints or color ﬁgure charges• Immediate publication on acceptance• Inclusion in PubMed, CAS, Scopus and Google Scholar• Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submits distributed under the terms of the Creative Commons Attribution 4.0.org/licenses/by/4.0/), which permits unrestricted use, distribution, andive appropriate credit to the original author(s) and the source, provide a link tochanges were made. The Creative Commons Public Domain Dedication waiverro/1.0/) applies to the data made available in this article, unless otherwise stated.Table 3 Administrative and clinical outcomes by fluid cohortOutcome/Complication Saline (n = 1558) % (n) Balanced (n = 1558) % (n) Unadjusted odds ratio (95 % CI) Adjusted odds ratio (95 % CI)Administrative OutcomesCardiac 8.66 (135) 4.43 (69) 0.488 (0.362–0.659) 0.387 (0.276–0.544)Hemorrhage 0.71 (11) 0.51 (8) 0.726 (0.291–1.809) 0.681 (0.264–1.757)Infectious 10.14 (158) 6.03 (94) 0.569 (0.436–0.742) 0.526 (0.396–0.699)Gastrointestinal 5.46 (85) 5.13 (80) 0.938 (0.685–1.284) 0.881 (0.636–1.220)Neurologic 1.16 (18) 0.83 (13) 0.72 (0.352–1.474) 0.585 (0.275–1.245)Acute renal failure 4.36 (68) 3.34 (52) 0.757 (0.524–1.093) 0.676 (0.447–1.023)Respiratory failure 5.46 (85) 3.47 (54) 0.622 (0.439–0.882) 0.624 (0.429–0.908)New organ failure 9.11 (142) 7.12 (111) 0.765 (0.59–0.991) 0.707 (0.506–0.986)Clinical OutcomesHospital mortality 3.27 (51) 1.03 (16) 0.307 (0.174–0.54) 0.373 (0.204–0.681)30–day readmissions 9.5 (148) 7.64 (119) 0.788 (0.612–1.014) 0.801 (0.618–1.036)60–day readmissions 13.54 (211) 10.91 (170) 0.782 (0.63–0.97) 0.804 (0.645–1.004)90–day readmissions 16.56 (258) 12.58 (196) 0.725 (0.593–0.886) 0.735 (0.598–0.904)CardiacDysrhythmia 10.65 (166) 6.87 (107) 0.618 (0.48–0.797) 0.632 (0.485–0.823)Cardiac stress 6.42 (100) 2.05 (32) 0.306 (0.204–0.458) 0.289 (0.188–0.483)Heart failure 4.04 (63) 1.48 (23) 0.356 (0.219–0.576) 0.447 (0.268–0.747)Hemorrhage/HematologicCoagulopathya 11.09 (150) 7.71 (106) 0.67 (0.516–0.87) 0.602 (0.450–0.806)Received blood transfusion 2.92 (46) 2.27 (36) 0.777 (0.5–1.209) 0.629 (0.389–1.018)Bleeding 20.09 (313) 19.96 (311) 0.992 (0.832–1.182) 1.134 (0.942–1.365)InfectiousPneumonia 6.03 (94) 2.12 (33) 0.337 (0.225–0.504) 0.349 (0.226–0.539)Sepsis 10.53 (164) 5.65 (88) 0.509 (0.389–0.666) 0.534 (0.401–0.711)Urinary tract infection 5.91 (92) 4.69 (73) 0.783 (0.571–1.074) 0.884 (0.632–1.237)Line infection 0.77 (12) 0 – –GastrointestinalCholecystitis 4.75 (74) 3.53 (55) 0.734 (0.514–1.048) 0.753 (0.517–1.098)RenalAcute Kidney Injury 5.46 (85) 4.43 (69) 0.803 (0.580–1.112) 1.052 (0.760–1.455)Electrolyte AbnormalitiesLow magnesium with replacement 4.36 (68) 2.12 (33) 0.474 (0.311–0.723) 0.565 (0.362–0.880)High magnesium 4.43 (69) 3.4 (53) 0.760 (0.528–1.095) 0.822 (0.553–1.221)Low potassium with replacement 14.12 (220) 7.51 (117) 0.494 (0.39–0.625) 0.510 (0.393–0.660)High potassium 9.44 (147) 6.87 (107) 0.708 (0.546–0.918) 0.848 (0.643–1.118)Low sodium 39.41 (614) 30.62 (477) 0.678 (0.585–0.787) 0.703 (0.602–0.821)High sodium 7 (109) 6.03 (94) 0.854 (0.642–1.135) 0.965 (0.710–1.311)Low calcium with replacement 1.16 (18) 0.77 (12) 0.664 (0.319–1.383) 1.125 (0.534–2.369)Metabolic AcidosisLactic (pH and lactate) 0.71 (11) 0.26 (4) 0.362 (0.115–1.139) 0.397 (0.106–1.487)Metabolic (pH and bicarbonate) 2.76 (43) 1.22 (19) 0.435 (0.252–0.75) 0.749 (0.399–1.403)Hyperchloremic (pH and chloride) 3.47 (54) 1.22 (19) 0.344 (0.203–0.583) 0.477 (0.262–0.868)aExcluded patients receiving warfarinShaw et al. Critical Care  (2016) 20:17 Page 2 of 3Fig. 2 legend, edit to: Administrative and clinical outcomes unadjusted and adjusted for APS, Elixhauser comorbidities of congestive heart failure,hypertension and lymphoma, admission source, census region, and payerShaw et al. Critical Care  (2016) 20:17 Page 3 of 3

Erratum to: Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome Critical Care (2016) 20:17 DOI 10.1186/s13054-016-1187-7

http://d-scholarship.pitt.edu/28908/1/art%253A10.1186%252Fs13054-016-1187-7.pdf

Erratum to: Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome Critical Care (2016) 20:17 DOI 10.1186/s13054-016-1187-7

Abstract

Similar works

Full text

Available Versions

D-Scholarship@Pitt